Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

2024 — Doctors recommend making fruits and vegetables a foundational part of the treatment of patients with hypertension. Diets high in fruits and vegetables are found to lower blood pressure ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Pulmonary artery denervation (PADN) may help lower high blood pressure in pulmonary hypertension, a meta-analysis of studies ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) 74th Annual Scientific Session and Expo in Chicago, March 29-31.

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...